DarioHealth Corp

NASDAQ DRIO

Download Data

DarioHealth Corp EBIT to Total Assets Ratio 3 year CAGR for the quarter ending March 31, 2024: 4.48%

DarioHealth Corp EBIT to Total Assets Ratio 3 year CAGR is 4.48% for the quarter ending March 31, 2024, a 111.38% change year over year. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • DarioHealth Corp EBIT to Total Assets Ratio for the quarter ending March 31, 2023 was -0.11, a 7.84% change year over year.
  • DarioHealth Corp EBIT to Total Assets Ratio for the quarter ending March 31, 2022 was -0.12, a -12.81% change year over year.
  • DarioHealth Corp EBIT to Total Assets Ratio for the quarter ending March 31, 2021 was -0.11, a 78.59% change year over year.
  • DarioHealth Corp EBIT to Total Assets Ratio for the quarter ending March 31, 2020 was -0.52, a -10.14% change year over year.
NASDAQ: DRIO

DarioHealth Corp

CEO Mr. Erez Raphael
IPO Date Oct. 6, 2014
Location United States
Headquarters 18 West 18th Street, New York, NY, United States, 10011
Employees 276
Sector Healthcare
Industry Health information services
Description

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Similar companies

SERA

Sera Prognostics Inc

NA

NA

FONR

Fonar Corporation

NA

NA

OLK

Olink Holding AB ADR

NA

NA

BDSX

Biodesix Inc

NA

NA

XGN

Exagen Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email